Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event
Lacutamab, partnered with Sobi, progressing toward first patient dosing
PACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC
Regulatory News:
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA)
Regulatory News:
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that
Regulatory News:
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8
New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027
€30 million equity financing completed to
The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions
Transaction closing triggers the USD 75 million upfront payment
Regulatory News:
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST /
Regulatory News:
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that
Regulatory News:
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (PARIS:IPH) (NASDAQ:IPHA) ("Innate" or the "Company") today announced that they have entered a
Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome
Markus Jensen appointed Chief Medical Officer,
Regulatory News:
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a strategic partnership to
Regulatory News:
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that
Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
Favorable safety profile observed to date, with limited hematological
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry
